MedWatch

Demant upgrades financial guidance again despite October's implant issues

Danish hearing giant Demant, which upgraded its financial guidance for the full year in August, has released an interim management statement covering the period year-to-date, in which the company has raised its financial expectations for 2021 in spite of having to recall cochlear implants a little over two weeks ago.

Photo: Jens Dresling/Politiken/Ritzau Scanpix

It was a wakeup call and an economic blow when hearing aid manufacturer Demant's surgical arm Oticon Medical had to recall a number of cochlear implants in addition to halting the further production of the devices in mid October.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs